Phase II Study of Abiraterone Acetate Plus Prednisone in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Demonstrating Radiographic Flare Discordant With Serologic Measures of Response

PURPOSE: Abiraterone is an oral inhibitor of CYP17, essential for androgen biosynthesis. This multicenter study assessed its efficacy in patients with CRPC without prior exposure to chemotherapy or CYP17 targeted therapy, and assessed the frequency of interpretation of bone scans discordant with PSA...

Full description

Saved in:
Bibliographic Details
Main Authors: Ryan, Charles J., Shah, Shreya, Efstathiou, Eleni, Smith, Matthew R., Taplin, Mary-Ellen, Bubley, Glenn J., Logothetis, Christopher J., Kheoh, Thian, Kilian, Christine, Haqq, Chris, Molina, Arturo, Small, Eric J.
Format: Artigo
Language:Inglês
Published: 2011
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3657705/
https://ncbi.nlm.nih.gov/pubmed/21632851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-0815
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items